PAVmed (NASDAQ:PAVM)‘s stock had its “buy” rating restated by investment analysts at Maxim Group in a research report issued on Friday, AnalystRatings.com reports. They presently have a $5.00 price target on the stock. Maxim Group’s price objective would suggest a potential upside of 113.68% from the company’s previous close.
Separately, ValuEngine raised PAVmed from a “sell” rating to a “hold” rating in a research note on Tuesday, March 3rd.
PAVM opened at $2.34 on Friday. The stock has a market capitalization of $118.19 million, a price-to-earnings ratio of -4.25 and a beta of 0.01. PAVmed has a fifty-two week low of $0.81 and a fifty-two week high of $3.45. The company has a fifty day moving average of $2.22 and a 200 day moving average of $1.65.
A number of hedge funds have recently added to or reduced their stakes in PAVM. Virtu Financial LLC purchased a new position in shares of PAVmed in the 4th quarter worth $25,000. M&R Capital Management Inc. bought a new position in shares of PAVmed in the 1st quarter valued at about $49,000. Levin Capital Strategies L.P. lifted its holdings in shares of PAVmed by 500.0% in the 4th quarter. Levin Capital Strategies L.P. now owns 60,000 shares of the company’s stock valued at $72,000 after acquiring an additional 50,000 shares during the last quarter. Buckingham Asset Management LLC purchased a new position in PAVmed in the first quarter worth about $79,000. Finally, Synovus Financial Corp bought a new stake in PAVmed during the first quarter worth approximately $79,000. Institutional investors and hedge funds own 5.88% of the company’s stock.
PAVmed Inc operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; EsoCheck, an non-invasive cell collection device and DNA biomarkers to detect esophageal cancer precursor; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube.
Featured Article: How to Track your Portfolio in Google Finance
Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.